secwatch.observer — SEC 8-K summary
======================================

Issuer:     enVVeno Medical Corp (NVNO)
CIK:        0001661053
Form:       8-K
Filed at:   2023-10-12T23:59:59+00:00
Accession:  0001493152-23-037065
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enVVeno raises $28M in PIPE financing with milestone-based warrants
-------------------------------------------------------------------

- Gross proceeds of $28M from sale of 3,844,704 shares, pre-funded warrants for 977,900 shares, and two tranches of warrants.
- Tranche A warrants (4,822,604 shares) at $6.945, expire 30 days post SAVVE top-line data or Oct 2024.
- Tranche B warrants (4,822,604 shares) at $8.334, expire 30 days post FDA PMA for VenoValve or Oct 2026.
- Net proceeds ~$25.9M; funds for VenoValve and enVVe development and working capital.
- Ladenburg Thalmann placement agent; 7% cash fee and warrants for 241,130 shares at $6.945.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661053/000149315223037065/0001493152-23-037065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661053/000149315223037065/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-037065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer